Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Azathioprine (AZA) has long been used in dermatology in treating autoimmune bullous
dermatoses and generalized eczematous disorders as well as some photodermatoses. Its
metabolic process inside human body and its side effects relies on genetic polymorphism of
some enzymes such as thiopurine s-methyltransferase (TPMT) and inosine triphosphate
pyrophosphatase gene (ITPA). This study aims to analyze the relative contribution of TMPT and
ITPA mutations to the development of toxicity induced by AZA treatment and to detect the
correlation of the genetic polymorphism.